QCM
ACAD icon

Quantinno Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Quantinno Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$541K Buy
21,371
+6,039
+39% +$133K ﹤0.01% 2942
2026
Q1 		$341K Buy
15,332
+5,244
+52% +$125K ﹤0.01% 2964
2025
Q4 		$269K Sell
10,088
-1,112
-10% -$26.6K ﹤0.01% 2894
2025
Q3 		$239K Buy
+11,200
New +$265K ﹤0.01% 2634

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quantinno Capital Management's ACAD Position: Q2 2026 in Review

Quantinno Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 39% in Q2 2026, buying an estimated $133K and bringing the position to 21,371 shares worth $541K. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

Quantinno Capital Management first reported a position in ACAD in Q3 2025 and has held it in 4 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Quantinno Capital Management held 21,371 shares of Acadia Pharmaceuticals worth $541K as of Q2 2026.
  • Quantinno Capital Management bought 6,039 Acadia Pharmaceuticals shares in Q2 2026, an estimated $133K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2942 holding.
  • Quantinno Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.